BioCryst Pharmaceuticals announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older in Israel.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst presents real-world data on the effects of ORLADEYO on HAE attacks
- BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
